Oghenetega A, Ghaffar A, Khokhar ME, Opene C, et al. Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma. J Gastroenterol Hepatol 2026 Aug 14. doi: 10.1111/jgh.70673.
PMID: 42601800